These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 34302770)

  • 1. Trypanocidal therapy among children infected by Trypanosoma cruzi. Serological and electrocardiographic changes over a mean twenty-five-years follow-up period.
    Suasnábar S; Olivera LV; Arias E; Bizai ML; Bottasso O; Arias E; Fabbro D
    Acta Trop; 2021 Oct; 222():106050. PubMed ID: 34302770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Electrocardiographic Abnormalities and Treatment with Benznidazole among Children with Chronic Infection by Trypanosoma cruzi: A Retrospective Cohort Study.
    Colantonio LD; Prado N; Segura EL; Sosa-Estani S
    PLoS Negl Trop Dis; 2016 May; 10(5):e0004651. PubMed ID: 27158908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trypanocidal drugs for late-stage, symptomatic Chagas disease (Trypanosoma cruzi infection).
    Vallejo M; Reyes PP; Martinez Garcia M; Gonzalez Garay AG
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD004102. PubMed ID: 33305846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Course of Chronic Trypanosoma cruzi Infection after Treatment Based on Parasitological and Serological Tests: A Systematic Review of Follow-Up Studies.
    Sguassero Y; Cuesta CB; Roberts KN; Hicks E; Comandé D; Ciapponi A; Sosa-Estani S
    PLoS One; 2015; 10(10):e0139363. PubMed ID: 26436678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trypanocide treatment among adults with chronic Chagas disease living in Santa Fe city (Argentina), over a mean follow-up of 21 years: parasitological, serological and clinical evolution.
    Fabbro DL; Streiger ML; Arias ED; Bizai ML; del Barco M; Amicone NA
    Rev Soc Bras Med Trop; 2007; 40(1):1-10. PubMed ID: 17486245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term cardiology outcomes in children after early treatment for Chagas disease, an observational study.
    González NL; Moscatelli G; Moroni S; Ballering G; Jurado L; Falk N; Bochoeyer A; Goldsman A; Grippo M; Freilij H; Garcia Bournissen F; Chatelain E; Altcheh J
    PLoS Negl Trop Dis; 2022 Dec; 16(12):e0010968. PubMed ID: 36534647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levels of anti-B13 antibodies over time in a cohort of chronic infected by Trypanosoma cruzi. Its relationship with specific treatment and clinical status.
    Olivera V; Bizai ML; Arias E; Suasnabar S; Bottasso O; Marcipar I; Fabbro D
    Acta Trop; 2021 Jun; 218():105908. PubMed ID: 33789152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trypanocide treatment of women infected with Trypanosoma cruzi and its effect on preventing congenital Chagas.
    Fabbro DL; Danesi E; Olivera V; Codebó MO; Denner S; Heredia C; Streiger M; Sosa-Estani S
    PLoS Negl Trop Dis; 2014 Nov; 8(11):e3312. PubMed ID: 25411847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nifurtimox versus benznidazole or placebo for asymptomatic Trypanosoma cruzi infection (Equivalence of Usual Interventions for Trypanosomiasis - EQUITY): study protocol for a randomised controlled trial.
    Villar JC; Herrera VM; Pérez Carreño JG; Váquiro Herrera E; Castellanos Domínguez YZ; Vásquez SM; Cucunubá ZM; Prado NG; Hernández Y
    Trials; 2019 Jul; 20(1):431. PubMed ID: 31307503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the ELISA-F29 test as an early marker of therapeutic efficacy in adults with chronic Chagas disease.
    Fabbro D; Velazquez E; Bizai ML; Denner S; Olivera V; Arias E; Pravia C; Ruiz AM
    Rev Inst Med Trop Sao Paulo; 2013; 55(3):. PubMed ID: 23740013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chagas cardiomyopathy associated with serological cure after trypanocidal treatment during childhood.
    Fernández ML; Hernández Y; Scollo K; Esteva MI; Riarte AR; Prado NG
    Rev Soc Bras Med Trop; 2018; 51(4):557-559. PubMed ID: 30133646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Interventional study in the natural evolution of Chagas disease. Evaluation of specific antiparasitic treatment. Retrospective-prospective study of antiparasitic therapy].
    Gallerano RR; Sosa RR
    Rev Fac Cien Med Univ Nac Cordoba; 2000; 57(2):135-62. PubMed ID: 12934232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Follow-up of an asymptomatic Chagas disease population of children after treatment with nifurtimox (Lampit) in a sylvatic endemic transmission area of Colombia.
    Bianchi F; Cucunubá Z; Guhl F; González NL; Freilij H; Nicholls RS; Ramírez JD; Montilla M; Flórez AC; Rosas F; Saavedra V; Silva N
    PLoS Negl Trop Dis; 2015 Feb; 9(2):e0003465. PubMed ID: 25723465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of Nifurtimox in the Treatment of Chagas Disease: a Long-Term Retrospective Cohort Study in Children and Adults.
    Falk N; Berenstein AJ; Moscatelli G; Moroni S; González N; Ballering G; Freilij H; Altcheh J
    Antimicrob Agents Chemother; 2022 May; 66(5):e0202121. PubMed ID: 35416710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Evaluation of an specific treatment for Trypanosoma cruzi in children, in the evolution of the indeterminate phase].
    Silveira CA; Castillo E; Castro C
    Rev Soc Bras Med Trop; 2000; 33(2):191-6. PubMed ID: 10881133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Longitudinal study and specific chemotherapy in children with chronic Chagas' disease, residing in a low endemicity area of Argentina].
    Streiger ML; del Barco ML; Fabbro DL; Arias ED; Amicone NA
    Rev Soc Bras Med Trop; 2004; 37(5):365-75. PubMed ID: 15361952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective, historically controlled study to evaluate the efficacy and safety of a new paediatric formulation of nifurtimox in children aged 0 to 17 years with Chagas disease one year after treatment (CHICO).
    Altcheh J; Castro L; Dib JC; Grossmann U; Huang E; Moscatelli G; Pinto Rocha JJ; Ramírez TE;
    PLoS Negl Trop Dis; 2021 Jan; 15(1):e0008912. PubMed ID: 33412557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nifurtimox chemotherapy: collateral effects in treated Trypanosoma cruzi infected patients.
    Murcia L; Carrilero B; Albajar Viñas P; Segovia M
    Rev Esp Quimioter; 2012 Mar; 25(1):74-5. PubMed ID: 22488545
    [No Abstract]   [Full Text] [Related]  

  • 19. Cardiac Evaluation in the Acute Phase of Chagas' Disease with Post-Treatment Evolution in Patients Attended in the State of Amazonas, Brazil.
    Ortiz JV; Pereira BVM; Couceiro KDN; Silva MRHDSE; Doria SS; Silva PRLD; Lira EDF; Guerra MDGVB; Guerra JAO; Ferreira JMBB
    Arq Bras Cardiol; 2019 Mar; 112(3):240-246. PubMed ID: 30916205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New Scheme of Intermittent Benznidazole Administration in Patients Chronically Infected with Trypanosoma cruzi: Clinical, Parasitological, and Serological Assessment after Three Years of Follow-Up.
    Álvarez MG; Ramírez JC; Bertocchi G; Fernández M; Hernández Y; Lococo B; Lopez-Albizu C; Schijman A; Cura C; Abril M; Laucella S; Tarleton RL; Natale MA; Castro Eiro M; Sosa-Estani S; Viotti R
    Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32571827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.